These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 21742807

  • 1. Gene set enrichment analysis unveils the mechanism for the phosphodiesterase 4B control of glucocorticoid response in B-cell lymphoma.
    Kim SW, Rai D, Aguiar RC.
    Clin Cancer Res; 2011 Nov 01; 17(21):6723-32. PubMed ID: 21742807
    [Abstract] [Full Text] [Related]

  • 2. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.
    Smith PG, Wang F, Wilkinson KN, Savage KJ, Klein U, Neuberg DS, Bollag G, Shipp MA, Aguiar RC.
    Blood; 2005 Jan 01; 105(1):308-16. PubMed ID: 15331441
    [Abstract] [Full Text] [Related]

  • 3. MicroRNA-124 regulates glucocorticoid sensitivity by targeting phosphodiesterase 4B in diffuse large B cell lymphoma.
    Kim J, Jeong D, Nam J, Aung TN, Gim JA, Park KU, Kim SW.
    Gene; 2015 Mar 01; 558(1):173-80. PubMed ID: 25576220
    [Abstract] [Full Text] [Related]

  • 4. A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma.
    Suhasini AN, Wang L, Holder KN, Lin AP, Bhatnagar H, Kim SW, Moritz AW, Aguiar RCT.
    Leukemia; 2016 Mar 01; 30(3):617-626. PubMed ID: 26503641
    [Abstract] [Full Text] [Related]

  • 5. Phosphodiesterase 4B is an effective therapeutic target in colorectal cancer.
    Kim DU, Kwak B, Kim SW.
    Biochem Biophys Res Commun; 2019 Jan 15; 508(3):825-831. PubMed ID: 30528730
    [Abstract] [Full Text] [Related]

  • 6. Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL.
    Kim SW, Rai D, McKeller MR, Aguiar RC.
    Blood; 2009 Jun 11; 113(24):6153-60. PubMed ID: 19369227
    [Abstract] [Full Text] [Related]

  • 7. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
    Petrich AM, Leshchenko V, Kuo PY, Xia B, Thirukonda VK, Ulahannan N, Gordon S, Fazzari MJ, Ye BH, Sparano JA, Parekh S.
    Clin Cancer Res; 2012 May 01; 18(9):2534-44. PubMed ID: 22338016
    [Abstract] [Full Text] [Related]

  • 8. Disruption of the Myc-PDE4B regulatory circuitry impairs B-cell lymphoma survival.
    Nam J, Kim DU, Kim E, Kwak B, Ko MJ, Oh AY, Park BJ, Kim YW, Kim A, Sun H, Jung Y, Lee JH, Shin HJ, Park I, Song DK, Jeong JY, Lee YH, Kim SW.
    Leukemia; 2019 Dec 01; 33(12):2912-2923. PubMed ID: 31138843
    [Abstract] [Full Text] [Related]

  • 9. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
    Xu ZZ, Xia ZG, Wang AH, Wang WF, Liu ZY, Chen LY, Li JM.
    Ann Hematol; 2013 Oct 01; 92(10):1351-8. PubMed ID: 23636313
    [Abstract] [Full Text] [Related]

  • 10. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
    Cooney JD, Lin AP, Jiang D, Wang L, Suhasini AN, Myers J, Qiu Z, Wölfler A, Sill H, Aguiar RCT.
    Clin Cancer Res; 2018 Mar 01; 24(5):1103-1113. PubMed ID: 29246942
    [Abstract] [Full Text] [Related]

  • 11. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
    Dong L, Lv H, Li W, Song Z, Li L, Zhou S, Qiu L, Qian Z, Liu X, Feng L, Meng B, Fu K, Wang X, Pan-Hammarström Q, Wang P, Wang X, Zhang H.
    Oncotarget; 2016 May 31; 7(22):33350-62. PubMed ID: 27147575
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of phosphodiesterase-4 (PDE4) activity triggers luminal apoptosis and AKT dephosphorylation in a 3-D colonic-crypt model.
    Tsunoda T, Ota T, Fujimoto T, Doi K, Tanaka Y, Yoshida Y, Ogawa M, Matsuzaki H, Hamabashiri M, Tyson DR, Kuroki M, Miyamoto S, Shirasawa S.
    Mol Cancer; 2012 Jul 25; 11():46. PubMed ID: 22830422
    [Abstract] [Full Text] [Related]

  • 13. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.
    Tiwari S, Dong H, Kim EJ, Weintraub L, Epstein PM, Lerner A.
    Biochem Pharmacol; 2005 Feb 01; 69(3):473-83. PubMed ID: 15652238
    [Abstract] [Full Text] [Related]

  • 14. Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma.
    Ezell SA, Wang S, Bihani T, Lai Z, Grosskurth SE, Tepsuporn S, Davies BR, Huszar D, Byth KF.
    Oncotarget; 2016 Feb 23; 7(8):9163-74. PubMed ID: 26824321
    [Abstract] [Full Text] [Related]

  • 15. UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma.
    Bedekovics T, Hussain S, Feldman AL, Galardy PJ.
    Blood; 2016 Mar 24; 127(12):1564-74. PubMed ID: 26702068
    [Abstract] [Full Text] [Related]

  • 16. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival.
    Uddin S, Hussain AR, Siraj AK, Manogaran PS, Al-Jomah NA, Moorji A, Atizado V, Al-Dayel F, Belgaumi A, El-Solh H, Ezzat A, Bavi P, Al-Kuraya KS.
    Blood; 2006 Dec 15; 108(13):4178-86. PubMed ID: 16946303
    [Abstract] [Full Text] [Related]

  • 17. Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppression.
    Sasi B, Ethiraj P, Myers J, Lin AP, Jiang S, Qiu Z, Holder KN, Aguiar RCT.
    Leukemia; 2021 Jul 15; 35(7):1990-2001. PubMed ID: 33299141
    [Abstract] [Full Text] [Related]

  • 18. Akt2 mediates glucocorticoid resistance in lymphoid malignancies through FoxO3a/Bim axis and serves as a direct target for resistance reversal.
    Xie M, Yang A, Ma J, Wu M, Xu H, Wu K, Jin Y, Xie Y.
    Cell Death Dis; 2019 Jan 01; 9(10):1013. PubMed ID: 30598523
    [Abstract] [Full Text] [Related]

  • 19. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
    Go H, Jang JY, Kim PJ, Kim YG, Nam SJ, Paik JH, Kim TM, Heo DS, Kim CW, Jeon YK.
    Oncotarget; 2015 Jun 20; 6(17):15035-49. PubMed ID: 25909227
    [Abstract] [Full Text] [Related]

  • 20. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, Claret FX, Rassidakis GZ.
    Cancer Res; 2006 Jul 01; 66(13):6589-97. PubMed ID: 16818631
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.